Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633236 | 1.00 | KMT2A (0.45) | KMT2AMEN1MMP13GPR119NR1H2 | |
| SCHEMBL344871 | 0.91 | KMT2A (0.49) | KMT2AMEN1MMP13GPR119NR1H2 | |
| SCHEMBL16654334 | 0.85 | STAT3 (0.42) | KMT2AMEN1 | |
| SCHEMBL13832628 | 0.84 | GPR119 (0.51) | KMT2AMEN1MMP13GPR119 | |
| SCHEMBL1502200 | 0.84 | GPR119 (0.51) | KMT2AMEN1MMP13GPR119 | |
| SCHEMBL13832841 | 0.84 | GPR119 (0.51) | KMT2AMEN1MMP13GPR119 | |
| SCHEMBL31282646 | 0.84 | KMT2A (0.47) | KMT2AMEN1MMP13GPR119NR1H2 | |
| SCHEMBL344239 | 0.83 | SCN9A (0.49) | KMT2AMEN1MMP13GPR119 | |
| SCHEMBL9068325 | 0.83 | SCN9A (0.49) | KMT2AMEN1MMP13GPR119 | |
| SCHEMBL344238 | 0.83 | SCN9A (0.49) | KMT2AMEN1MMP13GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-RE47193-E1 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10087174-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9428495-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087174-B2 | Selectively substituted quinoline compounds | SSB, TLR7, TLR8 | KMT2A 812/4885MEN1 4137/4885MMP13 3433/4885 |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | KMT2A 812/4885MEN1 4137/4885MMP13 3433/4885 |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | KMT2A 897/4885MEN1 4182/4885MMP13 3564/4885 |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | KMT2A 812/4885MEN1 4137/4885MMP13 3433/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | KMT2A 812/4885MEN1 4137/4885MMP13 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.